10-Q: Clene Reports Q3 2025 Results Amid Going Concern Doubts

Clene Inc. reported a reduced net loss in Q3 2025 and advanced its CNM-Au8 clinical programs for ALS and MS, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $16.9 million from $25.9 million in the prior year.
• Operating loss for the nine months ended September 30, 2025, decreased to $15.6 million from $24.4 million in the prior year.
• Cash and cash equivalents decreased to $7.9 million as of September 30, 2025, from $12.2 million as of December 31, 2024.
• The company received FDA guidance for a potential accelerated approval pathway for CNM-Au8 in ALS, despite initial data being deemed inadequate in September 2024.
• Plans are underway to submit an NDA for CNM-Au8 in ALS in Q1 2026, contingent on positive additional data and analyses.
• Phase 2 REPAIR-MS trial results showed CNM-Au8 significantly increased brain NAD+/NADH ratio, indicating improved energetic capacity.
• Preclinical data for CNM-Au8 in Parkinson's disease models demonstrated improved mitochondrial health, reduced inflammation, and restored cellular metabolism.
• The company raised $8.4 million in gross proceeds from its equity distribution agreement and $1.5 million from senior secured convertible promissory notes during the nine months ended September 30, 2025.
• Subsequent to September 30, 2025, an additional $1.2 million in gross proceeds was generated from the equity distribution agreement.
• Material weaknesses in internal control over financial reporting were identified, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: While there are positive clinical trial updates for MS and preclinical data for PD, the explicit 'going concern' warning, declining cash balance, and the need for significant additional funding for both operations and future clinical trials (especially the confirmatory ALS Phase 3) indicate a highly precarious financial position. The initial FDA feedback on ALS data being inadequate also points to significant challenges, despite subsequent guidance.

Positives

• Net loss significantly decreased to $16.9 million for the nine months ended September 30, 2025, from $25.9 million in the prior year.
• Operating loss decreased to $15.6 million for the nine months ended September 30, 2025, from $24.4 million in the prior year.
• Net cash used in operating activities improved to $13.7 million for the nine months ended September 30, 2025, from $16.5 million in the prior year.
• FDA provided guidance for a potential accelerated approval pathway for CNM-Au8 in ALS, outlining specific data requirements.
• Phase 2 REPAIR-MS trial showed CNM-Au8 significantly increased brain NAD+/NADH ratio (+0.449 units, p=0.0148), indicating improved brain energetic capacity in MS patients.
• Preclinical data for CNM-Au8 in Parkinson's disease models demonstrated improved mitochondrial health, reduced inflammation, restored cellular metabolism, and normalized gene expression without toxicity.
• The FDA expressed openness to considering cognition as a primary endpoint for a planned Phase 3 MS study, addressing a critical unmet medical need.
• Successful capital raises through equity distribution agreement ($8.4 million gross proceeds) and senior secured convertible promissory notes ($1.5 million) during the nine months ended September 30, 2025.

Negatives

• The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' and expects to not have sufficient cash within the next twelve months without additional financing.
• Total revenue decreased by 51% to $123,000 for the nine months ended September 30, 2025, from $251,000 in the prior year.
• Cash and cash equivalents decreased by $4.2 million to $7.9 million as of September 30, 2025, from $12.2 million as of December 31, 2024.
• Accumulated deficit increased to $299.1 million as of September 30, 2025, from $282.1 million as of December 31, 2024.
• Total stockholders' deficit increased to $12.4 million as of September 30, 2025, from $8.9 million as of December 31, 2024.
• The company is required to maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of the full balance of the 2024 SSCP Notes.
• Material weaknesses in internal control over financial reporting were identified, indicating a risk of financial misstatement.
• The NDA submission for CNM-Au8 in ALS is contingent on positive additional data and analyses, and the confirmatory Phase 3 trial (RESTORE-ALS) is contingent on funding.

Risks

• **Going Concern**: Substantial doubt about the company's ability to continue as a going concern due to significant losses, negative cash flows, and insufficient cash to sustain operations for the next twelve months without additional financing.
• **Funding Needs**: Inability to obtain additional financing (equity, debt, licensing, collaboration) could force delays, reductions, or elimination of R&D programs, product portfolio expansion, or commercialization efforts.
• **Regulatory Approval**: No assurance that current and future product candidates will receive necessary regulatory approvals or be commercially successful; denial or delay of approval would have a material adverse impact.
• **Cash Covenant**: Failure to maintain unrestricted cash and cash equivalents of at least $2.0 million could accelerate the full balance of the 2024 SSCP Notes.
• **Clinical Trial Reliance**: Reliance on third-party contract research organizations (CROs) and clinical vendors for performance.
• **Intellectual Property**: Risks related to the protection of intellectual property.
• **Litigation**: Potential for litigation or claims based on intellectual property, patent, product, regulatory, or other factors.
• **Employee Retention**: Ability to attract and retain employees necessary to support growth.
• **Contingent Liabilities**: Potential repayment obligations to the National Multiple Sclerosis Society (NMSS) of up to 450% of grants ($1.5 million for 2019 Grant, $3.0 million for 2023 Grant) upon commercial sales or other monetization events for CNM-Au8 for MS.
• **SSCPN Registration Fee**: Potential penalty of 2% of face value (up to 10% maximum, or $1.2 million) for failure to file and maintain an effective registration statement covering shares underlying the SSCPN Conversion Feature.
• **SSCPN Collateral Deficiency Fee**: Liability for any deficiency if collateral is sold during an event of default and proceeds are insufficient to satisfy obligations under SSCP Notes, plus additional 10% interest per annum.
• **Internal Control Weaknesses**: Material weaknesses in internal control over financial reporting could lead to material misstatements in financial statements.

Future Outlook

The company plans to submit an NDA for CNM-Au8 in ALS in the first quarter of 2026 under an accelerated approval pathway, assuming positive data from additional biomarker analyses and long-term survival data. A Type C meeting with the FDA is anticipated in Q1 2026 to review these analyses. A confirmatory Phase 3 trial, RESTORE-ALS, is planned for the first half of 2026, contingent on funding. For MS, the company plans to work with regulatory health authorities and experts to determine the proper path to advance CNM-Au8 into Phase 3, potentially focusing on cognition improvement. The company expects to incur additional losses and negative cash flows, requiring further financing to sustain operations and advance drug candidates. General and administrative expenses are anticipated to increase if an NDA is filed under accelerated approval to support commercialization, but would decrease if an NDA is not filed, due to cost-saving initiatives.

Management Comments

• "We expect to incur additional losses in the future, particularly as we advance the development of our clinical-stage drug candidates, continue research and development of our preclinical drug candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates."
• "We expect that within the next twelve months, we will not have sufficient cash and other resources on hand to sustain our current operations or meet our obligations as they become due unless we obtain additional financing."
• "We have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued."
• "We plan to continue dialogue with the FDA including presenting additional long-term survival data and biomarker changes with the goal of filing an NDA under an accelerated approval pathway."
• "We plan to work closely with regulatory health authorities from the FDA, European Medicines Agency and other international regulatory bodies, MS experts, and patient representatives to determine the proper path to advance CNM-Au8 into Phase 3 and potential future approval."

Industry Context

Clene Inc. operates in the highly challenging and capital-intensive neurodegenerative disease space, focusing on conditions like ALS, MS, and Parkinson's disease, which have significant unmet medical needs. The use of clean-surfaced nanotechnology (CSN) therapeutics represents an innovative approach to target cellular energy impairments common in these diseases. The company's strategy to leverage biomarker data (like NfL and NAD+/NADH ratio) and pursue accelerated approval pathways aligns with broader industry trends seeking faster drug development for severe conditions. However, the high costs and regulatory hurdles are typical for this sector, and the company's going concern warning highlights the inherent financial risks in clinical-stage biopharmaceutical development. The FDA's feedback on ALS data and openness to new endpoints for MS reflect the evolving regulatory landscape and the need for robust evidence of clinical benefit.

Corporate Governance

Related Party Transactions

• Sales of dietary supplement products (Zinc Factor, Gold Factor) to 4Life Research LLC, a stockholder and related party, under exclusive supply and royalty-bearing license agreements.
• Product revenue from related parties was $0 for Q3 2025 and $63,000 for the nine months ended September 30, 2025.
• Royalty revenue from related parties was $15,000 for Q3 2025 and $58,000 for the nine months ended September 30, 2025.
• Certain directors, executive officers, and affiliated entities contributed $1.3 million to private placements in October 2024.
• Senior Secured Convertible Promissory Notes (2024 SSCP Notes) were sold to related parties, including an entity controlled by a board member, 4Life, and an entity controlled by 4Life's chairman (also a subsidiary board member).

Stakeholder Impact

• **Shareholders**: Significant dilution risk due to ongoing equity financing, increased accumulated deficit, and substantial doubt about going concern. Potential for share price volatility based on clinical trial outcomes and funding news.
• **Employees**: Cost-saving initiatives include reducing employee compensation and eliminating staff positions, indicating potential job insecurity and impact on morale.
• **Customers (4Life Research LLC)**: Continued supply and license agreements for dietary supplements, but the company's financial health could impact long-term supply stability.
• **Creditors (SSCP Notes holders, DHCD, Advance Cecil Inc.)**: Risk of default due to going concern issues, though the company is currently not in violation of covenants. SSCP Notes holders have conversion and redemption features, and collateral.
• **Patients (ALS, MS, PD)**: Continued development of CNM-Au8 offers potential therapeutic benefits, but delays in regulatory approval or funding shortfalls could impact access to treatment.

Next Steps

• Complete additional data collection and analyses for ALS, including ACT-EAP NfL biomarker analyses, Placebo NfL biomarker analyses, Survival pharmacometric modeling, and additional ALS-specific biomarkers.
• Continue dialogue with the FDA, including presenting additional long-term survival data and biomarker changes for ALS.
• Request a Type C meeting with the FDA in Q1 2026 to review additional biomarker analyses for ALS.
• Submit an NDA for CNM-Au8 in ALS in Q1 2026 under an accelerated approval pathway, assuming positive data.
• Commence a confirmatory Phase 3 trial, RESTORE-ALS, in H1 2026, contingent on funding.
• Work with regulatory health authorities (FDA, EMA) and MS experts to determine the proper path to advance CNM-Au8 into Phase 3 for MS.
• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
• Raise additional funding through various means (equity, debt, licensing, ATM, warrant/option exercises).

Key Dates

Recommendation

The explicit "substantial doubt about the Company's ability to continue as a going concern" is a critical red flag for investors. Despite some positive clinical updates, the company's severe liquidity issues, declining cash balance, and increasing accumulated deficit indicate a highly unsustainable financial trajectory. The reliance on continuous capital raises, the contingency of future clinical trials on funding, and identified material weaknesses in internal controls further exacerbate the risk profile. The initial FDA feedback on ALS data being inadequate, even with subsequent guidance, suggests significant hurdles remain for regulatory approval. These factors collectively point to a high probability of further share price erosion and significant risk to capital.

Keywords

Clene Inc., CLNN, SEC Filing, 10-Q, Biotechnology, Pharmaceutical, Neurodegenerative Diseases, ALS, Multiple Sclerosis, Parkinson's Disease, CNM-Au8, Nanomedicine, Clinical Trials, FDA Approval, Going Concern, Financial Results, Research and Development, Equity Financing, Debt Financing, Warrants, NfL Biomarker, NAD+/NADH Ratio, Mitochondrial Health